Microscopic polyangiitis (PMP) is an uncommon condition that causes tiny blood vessels to be irritated. It is also a type of varicose vein. This results in extreme pain and swelling of the ankles and heels in both feet. PMP usually affects individuals within their fifties and sixties, but can occur in those of any age group. Many different things can lead up to a diagnosis of PMP, however, it is usually caused by another medical condition or some sort of accident. One common cause of PMP is trauma to an organ. Arthritis is one such disease, as is carpal tunnel syndrome, which can cause serious nerve damage in the hands and wrists. When an organ is damaged, inflammation occurs along with swelling and pain. The second type of Microscopic Polyangiitis test involves injecting a dye into a person's infected lungs. The lungs usually become swollen with fluid during this treatment. A chest x-ray will indicate any sign of infection. This type of Polyangiitis test is usually done on an outpatient basis.
Continuous research and development activities by major industry players are expected to drive growth of the global microscopic polyangiitis market during the forecast period. Key players in the market are focused on research and development activities, in order to innovate new products. For instance, in July 2018, InflaRx N.V., a Germany-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for its phase II clinical trials to analyze the safety and efficiency of IFX-1 indicated for the treatment anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis. Hence, such factors are expected to drive growth of the global microscopic polyangiitis market during the forecast period. Furthermore, the launch of new treatment methods is expected to boost the global microscopic polyangiitis market growth over the forecast period.
However, side effects such as skin thinning and intense pain combined with joint pain, diarrhea, and seizure are expected to hamper the global microscopic polyangiitis market growth over the forecast period. Furthermore, among regions, Europe is expected to witness significant growth in the global microscopic polyangiitis market during the forecast period. This is owing to rising product launches across the region. Asia Pacific is expected to register a robust growth rate over the forecast period, owing to rising product approvals in the region.
Key players involved in the global microscopic polyangiitis market are Genentech, Inc., TTY Biopharm Company Ltd., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), InflaRx N.V., Rituxan, Amerigen Pharmaceuticals Limited, and Bristol-Myers Squibb Company.
For instance, in October 2018, Rituxan received the U.S. FDA approval for two rare forms of vasculitis intended for the treatment of microscopic polyangiitis.
No comments:
Post a Comment